Zoetis Inc. (LON:0M3Q)

Market Cap	40.10B -34.9%
Revenue (ttm)	6.99B +2.7%
Net Income	1.97B +9.1%
EPS	4.42 +11.6%
Shares Out	n/a
PE Ratio	20.33
Forward PE	19.00
Dividend	1.52 (1.24%)
Ex-Dividend Date	Jan 20, 2026

Volume	1,195
Average Volume	5,538
Open	121.50
Previous Close	122.56
Day's Range	119.90 - 123.05
52-Week Range	114.00 - 179.11
Beta	0.97
RSI	47.40
Earnings Date	Feb 13, 2026

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1950
• Employees: 13,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M3Q

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD